Completed PHASE1 INTERVENTIONAL 2-arm NCT02084654

Exenatide and Weight Loss for Diabetes Prevention

Randomized Trial Investigating Exenatide for Diabetes Prevention in Obese, Insulin-Resistant Individuals With Prediabetes

Sponsor: Stanford University

Conditions Insulin Resistance Pre Diabetes

Interventions Exenatide 5 and 10 mcg 2 times a day placebo

Updated 6 times since 2017 Last updated: Nov 3, 2016 Started: Nov 30, 2007 Primary completion: Oct 31, 2012 Completion: Feb 28, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02084654, this PHASE1 trial focuses on Insulin Resistance and Pre Diabetes and remains completed. Sponsored by Stanford University, it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.